Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 243

1.

Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation.

Kitazono T, Ikeda T, Ogawa S, Nakagawara J, Minematsu K, Miyamoto S, Murakawa Y, Cavaliere M, Hayashi Y, Kidani Y, Okayama Y, Sunaya T, Sato S, Yamanaka S.

Heart Vessels. 2019 Sep 6. doi: 10.1007/s00380-019-01487-x. [Epub ahead of print]

PMID:
31492970
2.

Pre-conception status, obstetric outcome and use of medications during pregnancy of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) in Japan: multi-center retrospective descriptive study.

Tsuda S, Sameshima A, Sekine M, Kawaguchi H, Fujita D, Makino S, Morinobu A, Murakawa Y, Matsui K, Sugiyama T, Watanabe M, Suzuki Y, Nagahori M, Murashima A, Atsumi T, Oku K, Mitsuda N, Takei S, Miyamae T, Takahashi N, Nakajima K, Saito S; Ministry of Health Labour and Welfare Working Group for“Guideline for The Treatment of Rheumatoid Arthritis or Inflammatory Bowel Disease Bearing Women in Child-bearing Age.”.

Mod Rheumatol. 2019 Sep 4:1-26. doi: 10.1080/14397595.2019.1661592. [Epub ahead of print]

PMID:
31483178
3.

Codon bias confers stability to human mRNAs.

Hia F, Yang SF, Shichino Y, Yoshinaga M, Murakawa Y, Vandenbon A, Fukao A, Fujiwara T, Landthaler M, Natsume T, Adachi S, Iwasaki S, Takeuchi O.

EMBO Rep. 2019 Sep 3:e48220. doi: 10.15252/embr.201948220. [Epub ahead of print]

PMID:
31482640
4.

NET-CAGE characterizes the dynamics and topology of human transcribed cis-regulatory elements.

Hirabayashi S, Bhagat S, Matsuki Y, Takegami Y, Uehata T, Kanemaru A, Itoh M, Shirakawa K, Takaori-Kondo A, Takeuchi O, Carninci P, Katayama S, Hayashizaki Y, Kere J, Kawaji H, Murakawa Y.

Nat Genet. 2019 Sep;51(9):1369-1379. doi: 10.1038/s41588-019-0485-9. Epub 2019 Sep 2.

PMID:
31477927
5.

Unexpectedly lower proportion of placental transferred tocilizumab relative to whole immunoglobulin G: a case report.

Moriyama M, Wada Y, Minamoto T, Kondo M, Honda M, Murakawa Y.

Scand J Rheumatol. 2019 Aug 22:1-2. doi: 10.1080/03009742.2019.1639821. [Epub ahead of print] No abstract available.

PMID:
31436129
6.

Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings.

Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S, Murakawa Y, Iwashiro S, Kidani Y, Okayama Y, Sunaya T, Sato S, Yamanaka S.

J Thromb Thrombolysis. 2019 Aug 20. doi: 10.1007/s11239-019-01934-6. [Epub ahead of print]

PMID:
31432451
7.

Development of Dexlansoprazole Delayed-Release Capsules, a Dual Delayed-Release Proton Pump Inhibitor.

Grady H, Murakawa Y, Mulford D, Kukulka M.

J Pharm Sci. 2019 Aug 3. pii: S0022-3549(19)30489-7. doi: 10.1016/j.xphs.2019.07.023. [Epub ahead of print] Review.

PMID:
31386865
8.

Real-world outcomes of rivaroxaban treatment in patients with nonvalvular atrial fibrillation and worsening renal function.

Nakagawara J, Ikeda T, Ogawa S, Kitazono T, Minematsu K, Miyamoto S, Murakawa Y, Takeichi M, Kidani Y, Okayama Y, Sunaya T, Sato S, Yamanaka S.

J Cardiol. 2019 Jul 29. pii: S0914-5087(19)30173-X. doi: 10.1016/j.jjcc.2019.06.003. [Epub ahead of print]

PMID:
31371191
10.

Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A post hoc analysis of the SURPRISE study.

Kato M, Kaneko Y, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Nagasawa H, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K, Yokota I, Atsumi T, Takeuchi T.

Mod Rheumatol. 2019 Jun 7:1-8. doi: 10.1080/14397595.2019.1621026. [Epub ahead of print]

PMID:
31106666
11.

Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells.

Yamazaki H, Shirakawa K, Matsumoto T, Hirabayashi S, Murakawa Y, Kobayashi M, Sarca AD, Kazuma Y, Matsui H, Maruyama W, Fukuda H, Shirakawa R, Shindo K, Ri M, Iida S, Takaori-Kondo A.

Sci Rep. 2019 May 9;9(1):7122. doi: 10.1038/s41598-019-43575-y.

12.

Study design of nationwide Japanese Catheter Ablation Registry: Protocol for a prospective, multicenter, open registry.

Yamane T, Inoue K, Kusano K, Takegami M, Nakao YM, Miyamoto Y, Goya M, Uno K, Shoda M, Murakawa Y, Hirao K, Nogami A; J‐AB registry investigators.

J Arrhythm. 2019 Feb 4;35(2):167-170. doi: 10.1002/joa3.12163. eCollection 2019 Apr.

13.

Real-world outcomes of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS).

Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S, Murakawa Y, Takeichi M, Ohashi Y, Okayama Y, Sunaya T, Yamanaka S.

J Cardiol. 2019 Jul;74(1):60-66. doi: 10.1016/j.jjcc.2019.01.001. Epub 2019 Feb 8.

PMID:
30745002
14.

Influence of substrate modification in catheter ablation of atrial fibrillation on the incidence of acute complications: Analysis of 10 795 procedures in J-CARAF Study 2011-2016.

Murakawa Y, Yamane T, Goya M, Inoue K, Naito S, Kumagai K, Miyauchi Y, Morita N, Nogami A, Shoda M, Okumura K, Hirao K; Japanese Heart Rhythm Society Members.

J Arrhythm. 2018 Jul 6;34(4):435-440. doi: 10.1002/joa3.12081. eCollection 2018 Aug.

15.

Patient perceptions of curability and physician-reported disclosures of incurability in Japanese patients with unresectable/recurrent cancer: a cross-sectional survey.

Oishi T, Sato K, Morita T, Mack JW, Shimodaira H, Takahashi M, Takahashi S, Inoue A, Murakawa Y, Kawahara M, Ishioka C, Miyashita M.

Jpn J Clin Oncol. 2018 Oct 1;48(10):913-919. doi: 10.1093/jjco/hyy112.

PMID:
30102399
16.

2017 Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis.

Harigai M, Nagasaka K, Amano K, Bando M, Dobashi H, Kawakami T, Kishibe K, Murakawa Y, Usui J, Wada T, Tanaka E, Nango E, Nakayama T, Tsutsumino M, Yamagata K, Homma S, Arimua Y.

Mod Rheumatol. 2019 Jan;29(1):20-30. doi: 10.1080/14397595.2018.1500437. Epub 2018 Sep 10.

PMID:
30001655
17.
18.

Selective Activation of Alternative MYC Core Promoters by Wnt-Responsive Enhancers.

Bardales JA, Wieser E, Kawaji H, Murakawa Y, Darzacq X.

Genes (Basel). 2018 May 23;9(6). pii: E270. doi: 10.3390/genes9060270.

19.

Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study).

Kaneko Y, Kato M, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K, Takeuchi T; SURPRISE study group.

Ann Rheum Dis. 2018 Sep;77(9):1268-1275. doi: 10.1136/annrheumdis-2018-213416. Epub 2018 May 31.

20.

Intermittent Withdrawal of Oxaliplatin for Alleviating Neurotoxicity during Oxaliplatin-Based Chemotherapy for Japanese Patients with Inoperable or Metastatic Colorectal Cancer: A Phase 2 Multicenter Study.

Kato S, Imai H, Gamoh M, Takahata T, Ohori H, Yasuda K, Niitani T, Murakawa Y, Amagai K, Isobe H, Shindo Y, Kuroki M, Sakamoto Y, Shimodaira H, Yoshioka T, Ishioka C.

Tohoku J Exp Med. 2018 May;245(1):21-28. doi: 10.1620/tjem.245.21.

21.

Gene Signature-Based Approach Identified MEK1/2 as a Potential Target Associated With Relapse After Anti-TNFα Treatment for Crohn's Disease.

Gamo K, Okuzono Y, Yabuki M, Ochi T, Sugimura K, Sato Y, Sagara M, Hayashi H, Ishimura Y, Nishimoto Y, Murakawa Y, Shiokawa Z, Gotoh M, Miyazaki T, Ebisuno Y.

Inflamm Bowel Dis. 2018 May 18;24(6):1251-1265. doi: 10.1093/ibd/izy079.

22.

Design and baseline characteristics of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS).

Ogawa S, Minematsu K, Ikeda T, Kitazono T, Nakagawara J, Miyamoto S, Murakawa Y, Ohashi Y, Takeichi M, Okayama Y, Yamanaka S, Inuyama L.

J Arrhythm. 2018 Feb 7;34(2):167-175. doi: 10.1002/joa3.12034. eCollection 2018 Apr.

23.

European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice?

Dagres N, Chao TF, Fenelon G, Aguinaga L, Benhayon D, Benjamin EJ, Bunch TJ, Chen LY, Chen SA, Darrieux F, de Paola A, Fauchier L, Goette A, Kalman J, Kalra L, Kim YH, Lane DA, Lip GYH, Lubitz SA, Márquez MF, Potpara T, Pozzer DL, Ruskin JN, Savelieva I, Teo WS, Tse HF, Verma A, Zhang S, Chung MK, Bautista-Vargas WF, Chiang CE, Cuesta A, Dan GA, Frankel DS, Guo Y, Hatala R, Lee YS, Murakawa Y, Pellegrini CN, Pinho C, Milan DJ, Morin DP, Nadalin E, Ntaios G, Prabhu MA, Proietti M, Rivard L, Valentino M, Shantsila A.

J Arrhythm. 2018 Mar 23;34(2):99-123. doi: 10.1002/joa3.12050. eCollection 2018 Apr. No abstract available.

24.

Fluorescence-labeled liposome accumulation in injured colon of a mouse model of T-cell transfer-mediated inflammatory bowel disease.

Yamasaki M, Muraki Y, Nishimoto Y, Murakawa Y, Matsuo T.

Biochem Biophys Res Commun. 2017 Dec 9;494(1-2):188-193. doi: 10.1016/j.bbrc.2017.10.058. Epub 2017 Oct 13.

25.

Incidence and predictors of pericardial effusion as an early complication of catheter ablation for atrial fibrillation: The Japanese Catheter Ablation Registry of Atrial Fibrillation (J-CARAF).

Murakawa Y, Yamane T, Goya M, Inoue K, Naito S, Kumagai K, Miyauchi Y, Morita N, Nogami A, Shoda M, Okumura K, Hirao K; Japanese Heart Rhythm Society Members.

J Arrhythm. 2017 Oct;33(5):430-433. doi: 10.1016/j.joa.2017.04.009. Epub 2017 May 12.

26.

Hotspots of De Novo Point Mutations in Induced Pluripotent Stem Cells.

Yoshihara M, Araki R, Kasama Y, Sunayama M, Abe M, Nishida K, Kawaji H, Hayashizaki Y, Murakawa Y.

Cell Rep. 2017 Oct 10;21(2):308-315. doi: 10.1016/j.celrep.2017.09.060.

27.

HTLV-1 bZIP factor suppresses TDP1 expression through inhibition of NRF-1 in adult T-cell leukemia.

Takiuchi Y, Kobayashi M, Tada K, Iwai F, Sakurada M, Hirabayashi S, Nagata K, Shirakawa K, Shindo K, Yasunaga JI, Murakawa Y, Rajapakse V, Pommier Y, Matsuoka M, Takaori-Kondo A.

Sci Rep. 2017 Oct 9;7(1):12849. doi: 10.1038/s41598-017-12924-0.

28.

Report of periprocedural oral anticoagulants in catheter ablation for atrial fibrillation: The Japanese Catheter Ablation Registry of Atrial Fibrillation (J-CARAF).

Murakawa Y, Nogami A, Shoda M, Inoue K, Naito S, Kumagai K, Miyauchi Y, Yamane T, Morita N, Mitamura H, Okumura K, Hirao K; Japanese Heart Rhythm Society Members.

J Arrhythm. 2017 Jun;33(3):172-176. doi: 10.1016/j.joa.2016.10.002. Epub 2016 Oct 27.

29.

Genomic Instability of iPSCs: Challenges Towards Their Clinical Applications.

Yoshihara M, Hayashizaki Y, Murakawa Y.

Stem Cell Rev Rep. 2017 Feb;13(1):7-16. doi: 10.1007/s12015-016-9680-6. Review.

30.

The Lupus Autoantigen La Prevents Mis-channeling of tRNA Fragments into the Human MicroRNA Pathway.

Hasler D, Lehmann G, Murakawa Y, Klironomos F, Jakob L, Grässer FA, Rajewsky N, Landthaler M, Meister G.

Mol Cell. 2016 Jul 7;63(1):110-24. doi: 10.1016/j.molcel.2016.05.026. Epub 2016 Jun 23.

31.

[Pregnancy and lactation in rheumatoid arthritis].

Murakawa Y.

Nihon Rinsho. 2016 Jun;74(6):1035-41. Review. Japanese.

PMID:
27311198
32.

No Additional Effect of DPP-4 Inhibitor on Preventing Atrial Fibrosis in Streptozotocin-Induced Diabetic Rat as Compared With Sulfonylurea.

Hayami N, Sekiguchi A, Iwasaki YK, Murakawa Y, Yamashita T.

Int Heart J. 2016 May 25;57(3):336-40. doi: 10.1536/ihj.15-266. Epub 2016 Apr 28.

33.

Enhanced Identification of Transcriptional Enhancers Provides Mechanistic Insights into Diseases.

Murakawa Y, Yoshihara M, Kawaji H, Nishikawa M, Zayed H, Suzuki H, Fantom Consortium, Hayashizaki Y.

Trends Genet. 2016 Feb;32(2):76-88. doi: 10.1016/j.tig.2015.11.004. Epub 2016 Jan 15. Review.

PMID:
26780995
34.

Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study).

Kaneko Y, Atsumi T, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Nagasawa H, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K, Takeuchi T.

Ann Rheum Dis. 2016 Nov;75(11):1917-1923. doi: 10.1136/annrheumdis-2015-208426. Epub 2016 Jan 5.

35.

Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study.

Sada KE, Yamamura M, Harigai M, Fujii T, Takasaki Y, Amano K, Fujimoto S, Muso E, Murakawa Y, Arimura Y, Makino H; Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan.

Arthritis Res Ther. 2015 Nov 2;17:305. doi: 10.1186/s13075-015-0815-y.

36.

Current status of catheter ablation of atrial fibrillation in Japan: Summary of the 4th survey of the Japanese Catheter Ablation Registry of Atrial Fibrillation (J-CARAF).

Inoue K, Murakawa Y, Nogami A, Shoda M, Naito S, Kumagai K, Miyauchi Y, Yamane T, Morita N, Okumura K; Japanese Heart Rhythm Society Members.

J Cardiol. 2016 Jul;68(1):83-8. doi: 10.1016/j.jjcc.2015.08.011. Epub 2015 Sep 19.

37.

Successful Treatment of Refractory Electrical Storm With Landiolol After More Than 100 Electrical Defibrillations.

Kanamori K, Aoyagi T, Mikamo T, Tsutsui K, Kunishima T, Inaba H, Hayami N, Murakawa Y.

Int Heart J. 2015;56(5):555-7. doi: 10.1536/ihj.15-102. Epub 2015 Sep 4.

38.

Nationwide survey of catheter ablation for atrial fibrillation: The Japanese catheter ablation registry of atrial fibrillation (J-CARAF)-A report on periprocedural oral anticoagulants.

Murakawa Y, Nogami A, Shoda M, Inoue K, Naito S, Kumagai K, Miyauchi Y, Yamane T, Morita N, Mitamura H, Okumura K; Japanese Heart Rhythm Society׳s members.

J Arrhythm. 2015 Feb;31(1):29-32. doi: 10.1016/j.joa.2014.05.003. Epub 2014 Jul 5.

39.

Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults.

Kumagai Y, Murakawa Y, Hasunuma T, Aso M, Yuji W, Sakurai T, Noto M, Oe T, Kaneko A.

Int J Clin Pharmacol Ther. 2015 Oct;53(10):866-74. doi: 10.5414/CP202388.

PMID:
26308176
40.

RC3H1 post-transcriptionally regulates A20 mRNA and modulates the activity of the IKK/NF-κB pathway.

Murakawa Y, Hinz M, Mothes J, Schuetz A, Uhl M, Wyler E, Yasuda T, Mastrobuoni G, Friedel CC, Dölken L, Kempa S, Schmidt-Supprian M, Blüthgen N, Backofen R, Heinemann U, Wolf J, Scheidereit C, Landthaler M.

Nat Commun. 2015 Jul 14;6:7367. doi: 10.1038/ncomms8367.

41.

LARP4B is an AU-rich sequence associated factor that promotes mRNA accumulation and translation.

Küspert M, Murakawa Y, Schäffler K, Vanselow JT, Wolf E, Juranek S, Schlosser A, Landthaler M, Fischer U.

RNA. 2015 Jul;21(7):1294-305. doi: 10.1261/rna.051441.115. Epub 2015 May 22.

42.

Regnase-1 and Roquin Regulate a Common Element in Inflammatory mRNAs by Spatiotemporally Distinct Mechanisms.

Mino T, Murakawa Y, Fukao A, Vandenbon A, Wessels HH, Ori D, Uehata T, Tartey S, Akira S, Suzuki Y, Vinuesa CG, Ohler U, Standley DM, Landthaler M, Fujiwara T, Takeuchi O.

Cell. 2015 May 21;161(5):1058-1073. doi: 10.1016/j.cell.2015.04.029.

43.

[Germ cell tumors].

Murakawa Y.

Nihon Rinsho. 2015 Feb;73 Suppl 2:614-7. Japanese. No abstract available.

PMID:
25831833
44.

Dynamic nature of SecA and its associated proteins in Escherichia coli.

Adachi S, Murakawa Y, Hiraga S.

Front Microbiol. 2015 Feb 10;6:75. doi: 10.3389/fmicb.2015.00075. eCollection 2015.

45.

Roquin binding to target mRNAs involves a winged helix-turn-helix motif.

Schuetz A, Murakawa Y, Rosenbaum E, Landthaler M, Heinemann U.

Nat Commun. 2014 Dec 11;5:5701. doi: 10.1038/ncomms6701.

PMID:
25504471
46.

A variety of dicer substrates in human and C. elegans.

Rybak-Wolf A, Jens M, Murakawa Y, Herzog M, Landthaler M, Rajewsky N.

Cell. 2014 Nov 20;159(5):1153-1167. doi: 10.1016/j.cell.2014.10.040.

47.

Long QT syndrome associated with adrenal insufficiency in a patient with isolated adrenocorticotropic hormone deficiency.

Kanamori K, Yamashita R, Tsutsui K, Hara M, Murakawa Y.

Intern Med. 2014;53(20):2329-31. Epub 2014 Oct 15.

48.

Present profiles of novel anticoagulant use in Japanese patients with atrial fibrillation: insights from the Rivaroxaban Postmarketing Surveillance Registry.

Ogawa S, Ikeda T, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S, Murakawa Y, Iekushi K, Yamanaka S, Yamada T, Inuyama L; Rivaroxaban PostMarketing Surveillance Registry Investigators.

J Stroke Cerebrovasc Dis. 2014 Nov-Dec;23(10):2520-6. doi: 10.1016/j.jstrokecerebrovasdis.2014.03.006. Epub 2014 Sep 20.

PMID:
25245483
49.

Clinical and procedural predictors of early complications of ablation for atrial fibrillation: analysis of the national registry data.

Inoue K, Murakawa Y, Nogami A, Shoda M, Naito S, Kumagai K, Miyauchi Y, Yamane T, Morita N, Okumura K; Japanese Heart Rhythm Society Members.

Heart Rhythm. 2014 Dec;11(12):2247-53. doi: 10.1016/j.hrthm.2014.08.021. Epub 2014 Aug 15.

PMID:
25131666
50.

A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis?

Kondo M, Murakawa Y, Matsumura T, Matsumoto O, Taira M, Moriyama M, Sumita Y, Yamaguchi S.

Rheumatology (Oxford). 2014 Oct;53(10):1907-8. doi: 10.1093/rheumatology/keu234. Epub 2014 May 23. No abstract available.

PMID:
24859996

Supplemental Content

Loading ...
Support Center